J Gynecol Oncol.
2017 Jan;28(1):e25. 10.3802/jgo.2017.28.e25.
Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
- Affiliations
-
- 1Department of Gynecologic Oncology, Saitama Medical University International Medical Center, Saitama, Japan. koseih@saitama-med.ac.jp
- 2Department of Pathology, Saitama Medical University International Medical Center, Saitama, Japan.
- 3Department of Diagnostic Radiology, Saitama Medical University International Medical Center, Saitama, Japan.
- KMID: 2413861
- DOI: http://doi.org/10.3802/jgo.2017.28.e25
Abstract
- No abstract available.
MeSH Terms
-
Aged
Antineoplastic Agents/*administration & dosage/adverse effects
Carcinosarcoma/diagnostic imaging/*drug therapy
Female
Humans
Middle Aged
Ovarian Neoplasms/diagnostic imaging/*drug therapy
Pyrimidines/*administration & dosage/adverse effects
Sulfonamides/*administration & dosage/adverse effects
Tomography, X-Ray Computed
Uterine Neoplasms/diagnostic imaging/*drug therapy
Antineoplastic Agents
Pyrimidines
Sulfonamides
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Carcinosarcoma of Bladder: Report of a Case
- Durable Response to Pazopanib in a Patient with Metastatic Alveolar Soft Part Sarcoma
- Long-term recurrence-free survival in a patient with stage IVB uterine carcinosarcoma
- Pazopanib monotherapy in the treatment of pretreated, metastatic uterine sarcoma: a single-center retrospective study
- Comparative Evaluation of Second-Line Chemotherapy Agents for Advanced Soft Tissue Sarcoma: Gemcitabine/Docetaxel, Pazopanib, and Alternatives
